Tag: Nacimbio

Joint Stock Company National Immunobiological Company was founded on 29 October, 2013 as a Holding Company (an integrated entity) within Rostec State Corporation to operate in the area of immunobiological products development and production.
The holding was established to secure independence on imports for Russia’s healthcare and medicinal products supply system through the development of domestic production and science expertise. Prioritized products are immunobiological preparations and medicinal preparations for the treatment of infectious diseases.
Nacimbio’s mission is to ensure national sovereignty in manufacture and supply of medicinal products, medical supply that are not manufactured domestically, as the absence of their production poses a threat to the national healthcare security.

Increasing the production of medicines from its own substances is the medium term strategic goal of the Joint Stock Company Kurgan Society of Medical Preparations and Products Synthesis (part of Marathon Pharma and Nacimbio).

The new product of NPO Microgen, a subsidiary of Nacimbio pharmaceutical holding company (a part of Rostec Corporation), is the first Russian live influenza vaccine in liquid form that does not require intramuscular injections.

In January - May 2018, Nacimbio, a pharmaceutical holding company of Rostec Corporation, has supplied to all regions of Russia more than 1 million doses of vaccines for prevention of tick-borne encephalitis (TBE).

Nacimbio JSC, a pharmaceutical subsidiary of Rostec Corporation, signed four new contracts with the Russian Ministry of Health for 2018 supplies of blood-derived products under the Seven Nosologies program.

The Russian Ministry of Health will purchase a blood plasma product from Nacimbio, a subsidiary of Rostec Corporation, for more than 1 billion rubles following two auctions held by the Ministry for supply of this medicine.

"GMP news" is a Portal about international GMP Standard for pharmaceutical professionals and specialists, managers, and students. We provide coverage of the most important news in pharmaceutical trade accompanied by topical articles and press realeases from the forerunners of pharmaceutical industry. More about GMP news